PortfoliosLab logo
GH Research PLC (GHRS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

IE000GID8VI0

IPO Date

Jun 25, 2021

Highlights

Market Cap

$749.30M

EPS (TTM)

-$0.79

Gross Profit (TTM)

-$78.00K

EBITDA (TTM)

-$41.58M

Year Range

$6.00 - $20.50

Target Price

$34.50

Short %

16.47%

Short Ratio

20.55

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


GH Research PLC

Popular comparisons:
GHRS vs. SEEL GHRS vs. ACMR
Popular comparisons:

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

GH Research PLC (GHRS) returned 71.86% year-to-date (YTD) and -11.09% over the past 12 months.


GHRS

YTD

71.86%

1M

26.10%

6M

34.71%

1Y

-11.09%

3Y*

6.28%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of GHRS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202551.43%-4.43%8.88%-13.51%26.10%71.86%
202430.86%17.00%20.05%2.81%28.56%-17.25%6.35%-15.32%-36.29%21.08%10.25%-21.61%20.69%
2023-8.54%7.76%-16.60%5.13%33.33%5.94%10.83%-19.16%-5.46%-27.26%-14.64%-7.05%-40.33%
2022-27.22%-2.83%10.85%-20.39%-31.18%-0.40%11.82%39.34%-25.27%-12.39%7.47%-11.15%-58.34%
202112.88%-9.34%11.02%0.87%14.73%4.58%-11.86%21.19%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of GHRS is 44, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of GHRS is 4444
Overall Rank
The Sharpe Ratio Rank of GHRS is 4343
Sharpe Ratio Rank
The Sortino Ratio Rank of GHRS is 5151
Sortino Ratio Rank
The Omega Ratio Rank of GHRS is 4848
Omega Ratio Rank
The Calmar Ratio Rank of GHRS is 3737
Calmar Ratio Rank
The Martin Ratio Rank of GHRS is 4242
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for GH Research PLC (GHRS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

GH Research PLC Sharpe ratios as of May 31, 2025 (values are recalculated daily):

  • 1-Year: -0.11
  • All Time: -0.13

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of GH Research PLC compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


GH Research PLC doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the GH Research PLC. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the GH Research PLC was 81.15%, occurring on Dec 18, 2023. The portfolio has not yet recovered.

The current GH Research PLC drawdown is 56.88%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-81.15%Nov 10, 2021529Dec 18, 2023
-40.46%Sep 9, 202131Oct 21, 20216Oct 29, 202137
-26.62%Jul 2, 202117Jul 27, 202129Sep 7, 202146
-6.91%Nov 1, 20212Nov 2, 20215Nov 9, 20217
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of GH Research PLC over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of GH Research PLC, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 5.0% positive surprise.


-0.30-0.20-0.100.00202020212022202320242025
-0.19
-0.20
Actual
Estimate

Valuation

The Valuation section provides an overview of how GH Research PLC is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for GHRS relative to other companies in the Biotechnology industry. Currently, GHRS has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for GHRS in comparison with other companies in the Biotechnology industry. Currently, GHRS has a P/B value of 2.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items